Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3662 in Painful Diabetic Peripheral Neuropathy
NCT02372578Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- May 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clofutriben in diabetic peripheral neuropathy (DPN) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Change from Baseline in mean 24-hour average pain intensity as reported on the NPRS at 6 weeks. Started May 2015; status: terminated.
02
Drugs
clofutriben
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT02372578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372578.